Present and Future: Pharmacologic Treatment of Obesity

被引:39
作者
Glandt, Mariela [1 ]
Raz, Itamar [2 ]
机构
[1] Bronx Lebanon Hosp Ctr, Dept Endocrinol, Bronx, NY 10457 USA
[2] Univ Med Sch, Ctr Diabet, IL-12000 Jerusalem, Israel
关键词
D O I
10.1155/2011/636181
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity now presents one of the biggest health problems of our times. Diet and exercise are best for both prevention and treatment; unfortunately, both require much discipline and are difficult to maintain. Medications offer a possible adjunct, but their effect is modest, they are limited by side effects, and the weight loss lasts only as long as the drug is being taken, since as soon as treatment is stopped, the weight is regained. Sibutramine, a sympathomimetic medication which was available for long-term treatment, is the most recent of the drugs to be withdrawn from the market due to side effects; in this case it was an increased risk of cardiovascular events. This paper reviews those medications which are available for treatment of obesity, including many of those recently taken off the market. It also discusses some of the newer treatments that are currently being investigated.
引用
收藏
页数:13
相关论文
共 115 条
[1]   Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].
Amori, Renee E. ;
Lau, Joseph ;
Pittas, Anastassios G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206
[2]   Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial [J].
Anderson, JW ;
Greenway, FL ;
Fujioka, K ;
Gadde, KM ;
McKenney, J ;
O'Neil, PM .
OBESITY RESEARCH, 2002, 10 (07) :633-641
[3]  
[Anonymous], 2010, MED LETT DRUGS THER, V52, P25
[4]  
[Anonymous], 2010, BBC NEWS
[5]  
[Anonymous], 1998, NIH PUBLICATION, V98-4083
[6]   Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine [J].
Apfelbaum, M ;
Vague, P ;
Ziegler, O ;
Hanotin, C ;
Thomas, F ;
Leutenegger, E .
AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) :179-184
[7]   Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: A phase 2, randomized, placebo-controlled, dose-escalation study [J].
Aronne, Louis ;
Fujioka, Ken ;
Aroda, Vanita ;
Chen, Kim ;
Halseth, Amy ;
Kesty, Nicole C. ;
Burns, Colleen ;
Lush, Cameron W. ;
Weyer, Christian .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08) :2977-2983
[8]   Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial [J].
Aronne, Louis J. ;
Halseth, Amy E. ;
Burns, Colleen M. ;
Miller, Stephan ;
Shen, Larry Z. .
OBESITY, 2010, 18 (09) :1739-1746
[9]   Characterization of the effects of pancreatic polypeptide in the regulation of energy balance [J].
Asakawa, A ;
Inui, A ;
Yuzuriha, H ;
Ueno, N ;
Katsuura, G ;
Fujimiya, M ;
Fujino, MA ;
Niijima, A ;
Meguid, MM ;
Kasuga, M .
GASTROENTEROLOGY, 2003, 124 (05) :1325-1336
[10]   Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial [J].
Astrup, Arne ;
Madsbad, Sten ;
Breum, Leif ;
Jensen, Thomas J. ;
Kroustrup, Jens Peter ;
Larsen, Thomas Meinert .
LANCET, 2008, 372 (9653) :1906-1913